Improving viable low cost generic medication prescription rate in primary care pediatric practice

Sathyanarayan Sudhanthar1, Jane Turner1, Kripa Thakur1

  • 1Dept. of Pediatrics, College of Human Medicine, Michigan State University, USA.

Insights

This study successfully increased generic medication prescribing rates in pediatric clinics from 21% to over 65% in two years. This initiative improved healthcare quality and reduced costs by promoting generic drug use.

Area of Science:

  • Pediatric Healthcare Quality Improvement
  • Health Information Technology Integration
  • Pharmacoeconomics and Generic Drug Utilization

Background:

  • Pediatric clinics at MSU-CHM had consistently low generic medication prescription rates (approx. 21%) from 2009-2011.
  • Low generic prescribing rates were identified as an area for improvement in clinical practice.
  • A need existed to increase the prescription of cost-effective generic medications.

Purpose of the Study:

  • To significantly increase the prescribing rate of viable, low-cost, and approved generic medications within MSU-CHM general pediatric clinics.
  • To enhance the quality of care and reduce healthcare expenditures through increased generic drug utilization.

Main Methods:

  • Stakeholders (physicians, nurses, care managers, HIT) collaborated using the Plan-Do-Study-Act (PDSA) cycle.
  • Health Information Technology (HIT) identified top prescribed brand-name drugs and provider data.
  • Electronic Medical Records (EMR) were updated to include and clearly mark available generic alternatives for targeted drug classes (stimulants, allergy/asthma, psychotropics).

Main Results:

  • The overall generic prescription rate increased from 20% (Q1 2012) to 53% (12 months) and 65.5% (24 months).
  • This rate significantly surpassed the MSU health team's primary care average of 34.6%.
  • Prescription rates for brand-name medications concurrently decreased.

Conclusions:

  • The implemented project effectively and rapidly improved generic medication prescribing rates in a pediatric setting.
  • This initiative demonstrates a successful strategy for enhancing healthcare quality and achieving cost savings.
  • Continuous quality improvement through repeating the PDSA cycle is recommended to further optimize generic prescribing.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
372
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
733
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
702
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
330
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
461